FOXO1 inactivation induces cisplatin resistance in bladder cancer

We found that FOXO1‐shRNA sublines or FOXO1‐positive cells co–treated with a FOXO1 inhibitor were significantly more resistant to cisplatin treatment at pharmacological concentrations, compared with respective control sublines or those with mock treatment. Western blot demonstrated considerable incr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ide, Hiroki, Goto, Takuro, Teramoto, Yuki, Mizushima, Taichi, Jiang, Guiyang, Nagata, Yujiro, Inoue, Satoshi, Baras, Alexander S., Kashiwagi, Eiji, Miyamoto, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469822/
https://www.ncbi.nlm.nih.gov/pubmed/32678492
http://dx.doi.org/10.1111/cas.14557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469822/
https://www.ncbi.nlm.nih.gov/pubmed/32678492
http://dx.doi.org/10.1111/cas.14557

Ejemplares similares